Citable company snapshot
VERTEX PHARMACEUTICALS INC / MA's latest SEC-sourced 2026-06-30 period shows $3.33B in revenue and $1.10B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $3.33B | $2.99B | +11.6% |
| Operating Income | Jun 30, 2026 | $1.25B | $1.14B | +9.6% |
| Net Income | Jun 30, 2026 | $1.10B | $1.03B | +6.6% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $1.13B | $1.43B | -21.2% |
| Free Cash Flow (computed) | Jun 30, 2026 | $1.01B | $1.29B | -21.7% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Aug 4, 2026; accession 0000875320-26-000259.
VRTX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.